Connection

Yuko Palesch to Research Design

Back to Details
This is a "connection" page, showing publications Yuko Palesch has written about Research Design.
Yuko Palesch
Connection Strength
3.211
Research Design
  1. Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale. J Biopharm Stat. 2019; 29(1):82-97.
    View in: PubMed
    Score: 0.455
  2. Some common misperceptions about P values. Stroke. 2014 Dec; 45(12):e244-6.
    View in: PubMed
    Score: 0.353
  3. Continuous covariate imbalance and conditional power for clinical trial interim analyses. Contemp Clin Trials. 2014 May; 38(1):9-18.
    View in: PubMed
    Score: 0.337
  4. Quantitative comparison of randomization designs in sequential clinical trials based on treatment balance and allocation randomness. Pharm Stat. 2012 Jan-Feb; 11(1):39-48.
    View in: PubMed
    Score: 0.277
  5. Design and analysis plans. Front Neurol Neurosci. 2009; 25:76-77.
    View in: PubMed
    Score: 0.239
  6. Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005 Nov; 36(11):2410-4.
    View in: PubMed
    Score: 0.188
  7. An efficient multi-stage, single-arm Phase II futility design for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep; 5 Suppl 1:55-6.
    View in: PubMed
    Score: 0.174
  8. Stroke Recovery and Rehabilitation Research: Issues, Opportunities, and the National Institutes of Health StrokeNet. Stroke. 2017 03; 48(3):813-819.
    View in: PubMed
    Score: 0.103
  9. Power of an Adaptive Trial Design for Endovascular Stroke Studies: Simulations Using IMS (Interventional Management of Stroke) III Data. Stroke. 2016 12; 47(12):2931-2937.
    View in: PubMed
    Score: 0.102
  10. Multi-modality neuro-monitoring: conventional clinical trial design. Neurocrit Care. 2015 Jun; 22(3):369-77.
    View in: PubMed
    Score: 0.092
  11. Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke. 2014 May; 45(5):1408-14.
    View in: PubMed
    Score: 0.085
  12. High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocrit Care. 2013 Oct; 19(2):257-66.
    View in: PubMed
    Score: 0.082
  13. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013 Aug; 8(6):479-83.
    View in: PubMed
    Score: 0.081
  14. Covariate imbalance and adjustment for logistic regression analysis of clinical trial data. J Biopharm Stat. 2013; 23(6):1383-402.
    View in: PubMed
    Score: 0.078
  15. Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials. Pharm Stat. 2012 Jul-Aug; 11(4):310-7.
    View in: PubMed
    Score: 0.074
  16. Clinical trial design in the neurocritical care unit. Neurocrit Care. 2012 Feb; 16(1):6-19.
    View in: PubMed
    Score: 0.073
  17. Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012; 22(4):758-72.
    View in: PubMed
    Score: 0.072
  18. [Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II at Japan site: study design and advance construction of domestic research network]. Rinsho Shinkeigaku. 2012; 52(9):642-50.
    View in: PubMed
    Score: 0.072
  19. The albumin in acute stroke trial (ALIAS); design and methodology. Int J Stroke. 2007 Aug; 2(3):214-9.
    View in: PubMed
    Score: 0.053
  20. Lessons from adult stroke trials. Pediatr Neurol. 2006 Jun; 34(6):446-9.
    View in: PubMed
    Score: 0.049
  21. Analysis of clustered matched-pair data for a non-inferiority study design. Stat Med. 2003 Jan 30; 22(2):279-90.
    View in: PubMed
    Score: 0.039
  22. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. JAMA Netw Open. 2019 09 04; 2(9):e1910769.
    View in: PubMed
    Score: 0.031
  23. The National Institutes of Health StrokeNet: A User's Guide. Stroke. 2016 Feb; 47(2):301-3.
    View in: PubMed
    Score: 0.024
  24. Evolution of practice during the Interventional Management of Stroke III Trial and implications for ongoing trials. Stroke. 2014 Dec; 45(12):3606-11.
    View in: PubMed
    Score: 0.022
  25. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012 Oct; 60(4):451-7.
    View in: PubMed
    Score: 0.018
  26. The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report. Biochem Soc Trans. 2006 Dec; 34(Pt 6):1323-6.
    View in: PubMed
    Score: 0.013
  27. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33.
    View in: PubMed
    Score: 0.012
  28. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.